SCHEDULE: Eventide Asset Management Discloses 4.1% Stake in Mirum Pharma

Eventide Asset Management, along with Finny Kuruvilla and Robin C. John, reported a 4.1% beneficial ownership stake in Mirum Pharmaceuticals, Inc. as of December 31, 2025.

Summary

• Eventide Asset Management, LLC, Finny Kuruvilla, M.D., Ph.D., and Robin C. John collectively reported beneficial ownership of 2,093,582 shares of Mirum Pharmaceuticals, Inc. common stock.
• This represents 4.1% of the total outstanding common stock of Mirum Pharmaceuticals, Inc.
• Eventide Asset Management, LLC holds sole voting power and sole dispositive power over all 2,093,582 shares.
• Finny Kuruvilla, M.D., Ph.D., and Robin C. John share voting power and shared dispositive power over the same 2,093,582 shares.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing the control of Mirum Pharmaceuticals, Inc.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral disclosure, as Schedule 13G filings primarily report beneficial ownership and do not typically contain operational or financial performance updates.

Positives

• An institutional investor, Eventide Asset Management, maintains a significant stake in Mirum Pharmaceuticals, Inc., potentially signaling confidence in the company's long-term prospects.
• The beneficial ownership is below the 5% threshold, indicating it is a passive investment that does not trigger more extensive reporting requirements (like Schedule 13D, which implies intent to influence).

Risks

• No specific risks related to Mirum Pharmaceuticals, Inc.'s operations or financial health are disclosed in this ownership filing. The filing explicitly states the shares were not acquired for the purpose of changing or influencing control.

Future Outlook

No forward-looking statements or guidance are provided in this beneficial ownership report.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."
• "In accordance with Rule 13d-4 of the Securities Exchange Act of 1934, each of the persons filing this statement expressly disclaim the beneficial ownership of the securities covered by this statement and the filing of this report shall not be construed as an admission by such persons that they are the beneficial owners of such securities."

Industry Context

StockSavvy.ai notes that institutional ownership in biotechnology and pharmaceutical companies like Mirum Pharmaceuticals is common, reflecting investor interest in companies with potential drug pipelines or approved therapies. A 4.1% stake by an asset management firm indicates a notable, but not controlling, position.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by Eventide Asset Management could be viewed positively by other shareholders, as it indicates a professional investment firm sees value in Mirum Pharmaceuticals.

Key Dates

Keywords

Mirum Pharmaceuticals, Eventide Asset Management, Finny Kuruvilla, Robin C. John, beneficial ownership, Schedule 13G, common stock, institutional investment, pharmaceutical, biotech